Suppr超能文献

整合标准化全基因组序列分析与全球结核分枝杆菌抗生素耐药知识库。

Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.

机构信息

Critical Path Institute, 1730 E River Rd., Tucson, AZ, 85718, USA.

Joint unit Infection and Public Health FISABIO-CSISP/University of Valencia, Institute of integrative Systems Biology, Valencia, Spain.

出版信息

Sci Rep. 2018 Oct 18;8(1):15382. doi: 10.1038/s41598-018-33731-1.

Abstract

Drug-resistant tuberculosis poses a persistent public health threat. The ReSeqTB platform is a collaborative, curated knowledgebase, designed to standardize and aggregate global Mycobacterium tuberculosis complex (MTBC) variant data from whole genome sequencing (WGS) with phenotypic drug susceptibility testing (DST) and clinical data. We developed a unified analysis variant pipeline (UVP) ( https://github.com/CPTR-ReSeqTB/UVP ) to identify variants and assign lineage from MTBC sequence data. Stringent thresholds and quality control measures were incorporated in this open source tool. The pipeline was validated using a well-characterized dataset of 90 diverse MTBC isolates with conventional DST and DNA Sanger sequencing data. The UVP exhibited 98.9% agreement with the variants identified using Sanger sequencing and was 100% concordant with conventional methods of assigning lineage. We analyzed 4636 publicly available MTBC isolates in the ReSeqTB platform representing all seven major MTBC lineages. The variants detected have an above 94% accuracy of predicting drug based on the accompanying DST results in the platform. The aggregation of variants over time in the platform will establish confidence-graded mutations statistically associated with phenotypic drug resistance. These tools serve as critical reference standards for future molecular diagnostic assay developers, researchers, public health agencies and clinicians working towards the control of drug-resistant tuberculosis.

摘要

耐多药结核病仍然是一个严重的公共卫生威胁。ReSeqTB 平台是一个协作的、经过精心策划的知识库,旨在通过全基因组测序(WGS)与表型药敏试验(DST)和临床数据,对全球结核分枝杆菌复合群(MTBC)的变体数据进行标准化和聚合。我们开发了一个统一的分析变异管道(UVP)(https://github.com/CPTR-ReSeqTB/UVP),用于从 MTBC 序列数据中识别变体并分配谱系。在这个开源工具中,纳入了严格的阈值和质量控制措施。该管道使用经过充分验证的 90 个不同的 MTBC 分离株的数据集进行了验证,该数据集具有常规 DST 和 DNA 焦磷酸测序数据。UVP 与使用 Sanger 测序识别的变体的一致性为 98.9%,与谱系赋值的常规方法完全一致。我们分析了 ReSeqTB 平台中 4636 个公开的 MTBC 分离株,代表了所有七个主要的 MTBC 谱系。平台中检测到的变体基于平台中伴随的 DST 结果,对预测药物的准确率超过 94%。随着时间的推移,平台中变体的聚集将建立经过统计学验证的与表型药物耐药相关的置信度分级突变。这些工具为未来的分子诊断检测试剂盒开发者、研究人员、公共卫生机构和临床医生提供了重要的参考标准,有助于控制耐多药结核病。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验